Patritumab Deruxtecan (HER3-DXd) in EGFR-Mutated NSCLC Following EGFR TKI and Platinum-Based Chemotherapy: HERTHENA-Lung01
Expert oncologist Helena Yu, MD, reviews data from HERTHENA-Lung01 following the IASLC 2023 World Conference on Lung Cancer and considers how patritumab deruxtecan will fit into clinical practice.
Helena Yu Patritumab Deruxtecan Lung Cancer Non Small Cell Lung Cancer Egfr Mutation Egfr Lung Cancer
Source: onclive.com